MERS Fears Prompt Korean Ribavirin Plans
This article was originally published in PharmAsia News
Amid mounting fears over massive spreading of Middle East Respiratory Syndrome (MERS) in South Korea, where the number of confirmed cases totals 35 so far, pharma firms are discussing with the government a possible increase in production of ribavirin, which is known to be partly effective against the virus.
You may also be interested in...
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.
Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, progress in drug and vaccine development, lessons learned and the preparations being made to return to everyday life.